Literature DB >> 15941695

Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.

Jennifer S Haas1, Kathryn A Phillips, Eric P Gerstenberger, Andrew C Seger.   

Abstract

BACKGROUND: Generic substitution is one mechanism of curtailing prescription drug expenditures. Limited information is available about the potential savings associated with generic substitution.
OBJECTIVE: To estimate the potential savings associated with broad substitution of generic drugs.
DESIGN: Cross-sectional, nationally representative survey of noninstitutionalized adults.
SETTING: United States. PARTICIPANTS: Adults included in the Medical Expenditure Panel Survey Household Component, 1997-2000. MEASUREMENTS: Use of a multisource drug (that is, a drug available in a brand-name and > or =1 generic formulation) or a generic drug and the potential cost savings associated with broad generic substitution for all multisource products.
RESULTS: Fifty-six percent of all outpatient drugs were multisource products, accounting for 41% of total outpatient drug expenditures. Of these multisource drugs, 61% were dispensed as a generic. If a generic had been substituted for all corresponding brand-name outpatient drugs in 2000, the median annual savings in drug expenditures per person would have been 45.89 dollars (interquartile range, 10.35 dollars to 158.06) for adults younger than 65 years of age and 78.05 dollars (interquartile range, 19.94 dollars to 241.72 dollars) for adults at least 65 years of age. In these age groups, the national savings would have been 5.9 billion dollars (95% CI, 5.5 billion dollars to 6.2 billion dollars) and 2.9 billion dollars (CI, 2.6 billion dollars to 3.1 billion dollars), respectively, representing approximately 11% of drug expenditures. LIMITATIONS: Specific information about an individual's formulary was not available, so the authors could not estimate how much of the potential savings would benefit an individual or his or her health plan.
CONCLUSION: Although broad substitution of generic drugs would affect only a modest percentage of drug expenditures, it could result in substantial absolute savings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15941695     DOI: 10.7326/0003-4819-142-11-200506070-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  76 in total

1.  The doughnut hole: it's about medication adherence.

Authors:  Christianne L Roumie
Journal:  Ann Intern Med       Date:  2012-06-05       Impact factor: 25.391

2.  Impact of generic substitution decision support on electronic prescribing behavior.

Authors:  Shane P Stenner; Qingxia Chen; Kevin B Johnson
Journal:  J Am Med Inform Assoc       Date:  2010 Nov-Dec       Impact factor: 4.497

3.  Teaching Wisely.

Authors:  Adam J Obley; Katherine A Iossi; Linda L Humphrey
Journal:  J Grad Med Educ       Date:  2014-09

4.  Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.

Authors:  Enrique Seoane-Vazquez; Rosa Rodriguez-Monguio; Richard Hansen
Journal:  Clin Drug Investig       Date:  2016-04       Impact factor: 2.859

5.  Patients' attitudes towards and experiences of generic drug substitution in Norway.

Authors:  Inge Kjoenniksen; Morten Lindbaek; Anne Gerd Granas
Journal:  Pharm World Sci       Date:  2006-11-17

6.  Impact of Modified System of Objectified Judgement Analysis (SOJA) methodology on prescribing costs of ACE inhibitors.

Authors:  Ibrahim Alabbadi; Grainne Crealey; Michael Scott; Simon Baird; Tom Trouton; Jill Mairs; James McElnay
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

7.  On the hypothetical universal use of statins in primary prevention: an observational analysis on low-risk patients and economic consequences of a potential wide prescription rate.

Authors:  Alejandro Macchia; Javier Mariani; Marilena Romero; Fabio Robusto; Vito Lepore; Antonio Dettorre; Gianni Tognoni
Journal:  Eur J Clin Pharmacol       Date:  2015-02-11       Impact factor: 2.953

8.  The National e-Prescribing Patient Safety Initiative: removing one hurdle, confronting others.

Authors:  Michael A Fischer
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Resource Use Evaluation of Tobramycin Formulations in a State Medicaid Program.

Authors:  Shellie L Keast
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

10.  How can bedside rationing be justified despite coexisting inefficiency? The need for 'benchmarks of efficiency'.

Authors:  Daniel Strech; Marion Danis
Journal:  J Med Ethics       Date:  2012-12-20       Impact factor: 2.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.